Applied StemCell, Inc. is a leading stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT and CRISPR/Cas9.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/07/16 | $19,000,000 | Series D |
BioSciKin Hermed Capital Ping An Ventures Vi-Ventures | undisclosed |
